| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acknowledgements, Committees, Sponsors and Supporters
|
|
|
|
22 |
S4 |
p. iv5
|
article
|
| 2 |
agenda and abstracts of satellite symposia
|
|
|
|
22 |
S4 |
p. iv244-iv257
|
article
|
| 3 |
Aggressive lymphoma
|
|
|
|
22 |
S4 |
p. iv190-iv197
|
article
|
| 4 |
Apoptosis: from biology to therapeutic targeting*
|
O'Connor, O.A.
|
|
|
22 |
S4 |
p. iv76-iv79
|
article
|
| 5 |
Author index
|
|
|
|
22 |
S4 |
p. iv258-iv269
|
article
|
| 6 |
Autologous transplant
|
|
|
|
22 |
S4 |
p. iv168-iv170
|
article
|
| 7 |
Biology
|
|
|
|
22 |
S4 |
p. iv143-iv147
|
article
|
| 8 |
CLL
|
|
|
|
22 |
S4 |
p. iv171-iv174
|
article
|
| 9 |
CLL / myeloma
|
|
|
|
22 |
S4 |
p. iv242-iv243
|
article
|
| 10 |
Conference schedule
|
|
|
|
22 |
S4 |
p. iv10-iv24
|
article
|
| 11 |
Controversy I: Controversies in follicular lymphomas
|
|
|
|
22 |
S4 |
p. iv81-iv82
|
article
|
| 12 |
Controversy II: is interim PET useful in planning treatment for DLBCL?
|
|
|
|
22 |
S4 |
p. iv130
|
article
|
| 13 |
disclosures
|
|
|
|
22 |
S4 |
p. iv275-iv281
|
article
|
| 14 |
DLBCL
|
|
|
|
22 |
S4 |
p. iv223-iv230
|
article
|
| 15 |
Editorial Board
|
|
|
|
22 |
S4 |
p. ii-iii
|
article
|
| 16 |
Educational and Abstract Book of the 11th International conference on Malignant Lymphoma
|
|
|
|
22 |
S4 |
p. iv6
|
article
|
| 17 |
Educational book - list of Meet the Professor articels
|
|
|
|
22 |
S4 |
p. iv25
|
article
|
| 18 |
Epidemiology
|
|
|
|
22 |
S4 |
p. iv141-iv142
|
article
|
| 19 |
Epidemiology and risk factors
|
|
|
|
22 |
S4 |
p. iv203-iv205
|
article
|
| 20 |
“Focus on…” Session: allogeneic transplantation
|
|
|
|
22 |
S4 |
p. iv94-iv95
|
article
|
| 21 |
“Focus on…” session: high-dose chemotherapy
|
|
|
|
22 |
S4 |
p. iv115-iv116
|
article
|
| 22 |
“Focus on…” Session: immunodeficiency and lymphoma
|
|
|
|
22 |
S4 |
p. iv98-iv99
|
article
|
| 23 |
“Focus on…” session: lymphoma in the elderly
|
|
|
|
22 |
S4 |
p. iv117-iv118
|
article
|
| 24 |
“Focus on…” session: monoclonal antibodies
|
|
|
|
22 |
S4 |
p. iv131-iv132
|
article
|
| 25 |
“Focus on…” session: new drug combinations
|
|
|
|
22 |
S4 |
p. iv119-iv120
|
article
|
| 26 |
“Focus on…” Session: PET use in lymphoma
|
|
|
|
22 |
S4 |
p. iv96-iv97
|
article
|
| 27 |
“Focus on…” session: plasma cell disorders and Waldenström macroglobulinemia
|
|
|
|
22 |
S4 |
p. iv121-iv122
|
article
|
| 28 |
“Focus on…” Session: primary CNS lymphoma
|
|
|
|
22 |
S4 |
p. iv92-iv93
|
article
|
| 29 |
“Focus on…” session: primary mediastinal BCL
|
|
|
|
22 |
S4 |
p. iv133-iv134
|
article
|
| 30 |
“Focus on…” Session: radiotherapy and early stage
|
|
|
|
22 |
S4 |
p. iv90-iv91
|
article
|
| 31 |
“Focus on…” Session: update of randomised trials
|
|
|
|
22 |
S4 |
p. iv88-iv89
|
article
|
| 32 |
Genomics
|
|
|
|
22 |
S4 |
p. iv148-iv152
|
article
|
| 33 |
Hodgkin lymphoma
|
|
|
|
22 |
S4 |
p. iv238-iv239
|
article
|
| 34 |
Hodgkin lymphoma
|
|
|
|
22 |
S4 |
p. iv179-iv182
|
article
|
| 35 |
I. Epidemiology of adult non-Hodgkin lymphoma
|
Boffetta, P.
|
|
|
22 |
S4 |
p. iv27-iv31
|
article
|
| 36 |
III. Role of allotransplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia
|
Dreger, P.
|
|
|
22 |
S4 |
p. iv36-iv39
|
article
|
| 37 |
II. New perspectives and challenges in the understanding of mantle cell lymphoma
|
Navarro, A.
|
|
|
22 |
S4 |
p. iv32-iv35
|
article
|
| 38 |
Imaging
|
|
|
|
22 |
S4 |
p. iv215-iv216
|
article
|
| 39 |
Immunodeficiency lymphoma
|
|
|
|
22 |
S4 |
p. iv235-iv237
|
article
|
| 40 |
Indolent lymphoma
|
|
|
|
22 |
S4 |
p. iv183-iv189
|
article
|
| 41 |
Indolent NHL
|
|
|
|
22 |
S4 |
p. iv217-iv219
|
article
|
| 42 |
IV. Epigenetics: what it is and what it can bring
|
Esteller, M.
|
|
|
22 |
S4 |
p. iv40
|
article
|
| 43 |
IX. Chronic lymphocytic leukemia for the clinician
|
Hallek, M.
|
|
|
22 |
S4 |
p. iv54-iv56
|
article
|
| 44 |
Key note lectures
|
|
|
|
22 |
S4 |
p. iv80
|
article
|
| 45 |
Lymphoma biology
|
|
|
|
22 |
S4 |
p. iv206-iv210
|
article
|
| 46 |
Mantle cell lymphoma
|
|
|
|
22 |
S4 |
p. iv220-iv222
|
article
|
| 47 |
Mantle cell lymphoma
|
|
|
|
22 |
S4 |
p. iv161-iv163
|
article
|
| 48 |
New drugs
|
|
|
|
22 |
S4 |
p. iv198-iv202
|
article
|
| 49 |
New drugs and mechanism
|
|
|
|
22 |
S4 |
p. iv240-iv241
|
article
|
| 50 |
Pathology and clinico-pathological correlations
|
|
|
|
22 |
S4 |
p. iv153-iv156
|
article
|
| 51 |
Pathology and clinico-pathological correlations
|
|
|
|
22 |
S4 |
p. iv211-iv214
|
article
|
| 52 |
Pediatric lymphoma
|
|
|
|
22 |
S4 |
p. iv175-iv178
|
article
|
| 53 |
PET
|
|
|
|
22 |
S4 |
p. iv157-iv160
|
article
|
| 54 |
Satellite symposia schedule
|
|
|
|
22 |
S4 |
p. iv9
|
article
|
| 55 |
Session 7: aggressive lymphoma
|
|
|
|
22 |
S4 |
p. iv106-iv107
|
article
|
| 56 |
Session 10: CLL
|
|
|
|
22 |
S4 |
p. iv123-iv124
|
article
|
| 57 |
Session 15: Hodgkin lymphoma
|
|
|
|
22 |
S4 |
p. iv138-iv140
|
article
|
| 58 |
Session 13: indolent lymphoma
|
|
|
|
22 |
S4 |
p. iv128-iv129
|
article
|
| 59 |
Session 12: lymphoma and apoptosis
|
|
|
|
22 |
S4 |
p. iv127
|
article
|
| 60 |
Session 2: Lymphoma and its microenvironment
|
|
|
|
22 |
S4 |
p. iv84-iv85
|
article
|
| 61 |
Session 5: lymphoma and the immune system
|
|
|
|
22 |
S4 |
p. iv102-iv103
|
article
|
| 62 |
Session 1: Lymphoma epidemiology
|
|
|
|
22 |
S4 |
p. iv83
|
article
|
| 63 |
Session 4: lymphoma genomics
|
|
|
|
22 |
S4 |
p. iv100-iv101
|
article
|
| 64 |
Session 3: Mantle cell lymphoma
|
|
|
|
22 |
S4 |
p. iv86-iv87
|
article
|
| 65 |
Session 8: pathology and clinicopathological correlations
|
|
|
|
22 |
S4 |
p. iv108-iv111
|
article
|
| 66 |
Session 9: pediatric lymphoma
|
|
|
|
22 |
S4 |
p. iv112-iv114
|
article
|
| 67 |
Session 14: signalling pathways in lymphoma
|
|
|
|
22 |
S4 |
p. iv135-iv137
|
article
|
| 68 |
Session 6: targeting the lymphoma cell surface
|
|
|
|
22 |
S4 |
p. iv104-iv105
|
article
|
| 69 |
Session 11: T-cell lymphomas
|
|
|
|
22 |
S4 |
p. iv125-iv126
|
article
|
| 70 |
Stem cell transplant
|
|
|
|
22 |
S4 |
p. iv232-iv234
|
article
|
| 71 |
Subject index
|
|
|
|
22 |
S4 |
p. iv270-iv274
|
article
|
| 72 |
Summary of the conference schedule
|
|
|
|
22 |
S4 |
p. iv7-iv8
|
article
|
| 73 |
Table of Contents
|
|
|
|
22 |
S4 |
p. iv-v
|
article
|
| 74 |
T-cell lymphoma
|
|
|
|
22 |
S4 |
p. iv164-iv167
|
article
|
| 75 |
T-cell lymphoma
|
|
|
|
22 |
S4 |
p. iv231
|
article
|
| 76 |
VI. DNA microarray technology. Principles and application to the analysis of malignant tumours (with special emphasis on lymphoma)
|
Fey, M.F.
|
|
|
22 |
S4 |
p. iv44-iv46
|
article
|
| 77 |
VIII. Radioimmunotherapy in malignant lymphoma: an underused tool?
|
Hagenbeek, A.
|
|
|
22 |
S4 |
p. iv51-iv53
|
article
|
| 78 |
VII. The role of the microenvironment in lymphoid cancers
|
Gascoyne, R.D.
|
|
|
22 |
S4 |
p. iv47-iv50
|
article
|
| 79 |
V. Primary CNS lymphoma in immunocompetent patients
|
Marturano, E.
|
|
|
22 |
S4 |
p. iv41-iv43
|
article
|
| 80 |
XI. Distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma
|
Jack, A.
|
|
|
22 |
S4 |
p. iv61-iv63
|
article
|
| 81 |
XII. Gray zone lymphomas: a biological experiment, and a challenge for diagnosis and management
|
Eberle, Franziska C.
|
|
|
22 |
S4 |
p. iv64-iv66
|
article
|
| 82 |
XIII. The role of immunotherapy in the treatment of lymphoma
|
Levy, R.
|
|
|
22 |
S4 |
p. iv67
|
article
|
| 83 |
XIV. T- and NK-cell lymphoproliferative disorders
|
Rosen, S.
|
|
|
22 |
S4 |
p. iv68-iv71
|
article
|
| 84 |
XV. Primary cutaneous lymphomas
|
Willemze, R.
|
|
|
22 |
S4 |
p. iv72-iv75
|
article
|
| 85 |
X. When should radiotherapy be used in lymphoma?
|
Illidge, T.
|
|
|
22 |
S4 |
p. iv57-iv60
|
article
|
Journal description